Cabinet memorandum to address healthcare staffing needs ready - Dzulkefly
PAPAR (July 23): The Ministry of Health (MOH) has prepared briefing notes and a memorandum to be presented to the Cabinet to address the shortage of personnel in the national healthcare sector, said its minister Datuk Seri Dr Dzulkefly Ahmad.
He said the ministry is committed to resolving the filling of 4,352 positions to meet the healthcare needs of the people, as announced by Prime Minister Datuk Seri Anwar Ibrahim Wednesday.
'We are aware that the shortage of personnel is a real issue and must be addressed. I am personally committed to expediting the appointment process for those currently on contract to be absorbed into permanent positions without having to wait by cohort.
'We are identifying ways to reduce this deficit or close the gap, and to implement redistribution or resolve the long-standing issue of maldistribution. I have inherited this situation, but I am determined to address it within a reasonable timeframe,' he said.
He was speaking to reporters after attending the Community Engagement Day event at the National Information Dissemination Centre in Kampung Langkuas, Kinarut, near here Wednesday.
Also present were Communications Minister Datuk Fahmi Fadzil, Ministry of Communications Secretary-General Datuk Mohamad Fauzi Md Isa, and MOH Secretary-General Datuk Seri Suriani Ahmad.
When announcing government initiatives for Malaysians today, the Prime Minister said the government would expedite the filling of 4,352 positions at healthcare facilities, including the appointment of contract doctors this year, in response to urgent needs in the country's healthcare sector.
However, Dzulkefly clarified that the responsibility for position appointments does not lie with the ministry, but rather under the jurisdiction of the Public Service Department (JPA) and Public Services Commission (SPA), though he is confident these agencies are committed to fulfilling the staffing needs of the health sector.
He added that the MOH is also striving to boost the morale of healthcare staff by maintaining the 42-hour work week for nurses, housemen (PPS), and medical officers (MOs). – Bernama
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
7 minutes ago
- Malay Mail
Malaysia already classifies etomidate as Group B poison amid rising misuse concerns in Singapore, says health minister
PUTRAJAYA, July 30 — Health Minister Datuk Seri Dzulkefly Ahmad today clarified that etomidate is already classified under Group B poisons in Malaysia. He explained that any future policy decisions will be made based on evidence rather than public alarm. 'Regarding the side effects of etomidate reported in Singapore, I'm fully aware of the case. The product in question is already listed under Group B poisons in Malaysia. 'It is considered an active substance used in clinical practice. It's not an issue of classification, as it is already categorised appropriately,' he said in a press conference after officiating the National Health Technology Assessment Conference 2025. Dzulkefly said there is no controversy surrounding etomidate's use or classification in Malaysia. He added that while the government is open to reviewing any proposals concerning the substance, all decisions will be guided by rigorous, evidence-based evaluation rather than isolated incidents. 'I don't wish to comment further on the matter, even in cases involving death and so on; we do not base our decisions on such incidents alone. 'Our decision-making process remains grounded in what is actually substantiated, guided by a rigorous, evidence-based approach. I have no objections to reviewing the matter, but our approach will always prioritise scientific evidence and clinical standards,' he said. On July 20, Singapore Health Minister Ong Ye Kung announced plans to classify etomidate as a Class C substance under the Misuse of Drugs Act, citing growing concern over the rise in vaping products laced with the anaesthetic, CNN reported. He said the trend has alarmed key agencies, including the Health Ministry and the Ministry of Home Affairs due to its potential health and safety risks. On Friday, The Straits Times reported that Singapore's Health Sciences Authority (HSA) confirmed etomidate was found in the blood samples of two individuals involved in a fatal road accident on Punggol Road in May. Police had recovered 42 e-vaporisers and over 1,200 pods from the vehicle, with tests by HSA confirming that some of the products contained the drug.
Malay Mail
38 minutes ago
- Malay Mail
Public education on medicine price transparency will persist despite judicial review by doctors, says health minister
PUTRAJAYA, July 30 — Health Minister Datuk Seri Dzulkefly Ahmad today said education efforts on medicine price transparency will continue without interruption, despite medical practitioners pursuing a judicial review against the government's price control policy. In this case, Dzulkefly said the ministry supports the right to pursue judicial review, but advocacy efforts must continue while the legal process takes its course. 'As a minister, I welcome and respect the judicial process. We were also previously subjected to judicial review under the Medicines (Price Control) Act 852. 'As such, I support the idea of allowing the process to proceed. In the meantime, our educational and advocacy efforts must continue. We cannot afford to pause just because a judicial review is underway,' he told reporters in a press conference after officiating the National Health Technology Assessment Conference 2025 here. He explained that suspending all enforcement would create a gap, emphasising that the ministry's educational enforcement must continue until the court reaches a decision. Yesterday, seven medical associations and a general practitioner from Sabah applied for a judicial review against a government directive requiring private clinics to display retail drug prices, arguing that the directive oversteps ministerial authority and may undermine professional medical practice. The application was filed in the Kuala Lumpur High Court last Thursday by the Association of Private Practitioners, Sabah (APPS), the Malaysian Medical Association (MMA), the Malaysian Association for the Advancement of Functional and Interdisciplinary Medicine (Maafim), the Organisation of Malaysian Muslim Doctors (Perdim), the Federation of Private Medical Practitioners Associations Malaysia (FPMPAM), the Malaysian Private Dental Practitioners' Association (MPDPA), the Society of Private Medical Practitioners Sarawak (SPMPS) and Dr Saifulbahri Ahmad. The applicants, who named Dzulkefly, Domestic Trade and Cost of Living Minister Datuk Armizan Mohd Ali, and the federal government as respondents, argued that the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025 exceeds ministerial powers, as Section 10 of the Act does not cover medications administered during treatment under Section 19 of the Poisons Act 1952. Gazetted on May 1, the Price Marking for Drug Order 2025 came into force with a three-month window before full enforcement begins on August 1.
The Star
an hour ago
- The Star
Medicine price display rule to proceed despite judicial review, says Health Minister
PUTRAJAYA: The implementation of the medicine price display rule will go ahead on Aug 1, despite a judicial review filed by doctors to challenge the order, says Datuk Seri Dzulkefly Ahmad. The Health Minister stated that although doctors want the rule, which took effect on May 1, revoked due to its impact on small clinics and lack of proper consultation, the implementation will proceed. "We are aware of the application for the judicial review. Nevertheless, the implementation of the order will proceed," he told reporters at a press conference after launching the National Health Technology Assessment (NHTA) Conference 2025 here on Wednesday (July 30). He was asked to comment on the judicial review filed by the Association of Private Practitioners, Sabah (APPS), the Malaysian Medical Association (MMA), the Malaysian Association for the Advancement of Functional and Interdisciplinary Medicine (Maafim), the Organisation of Malaysian Muslim Doctors (Perdim), the Federation of Private Medical Practitioners Associations Malaysia (FPMPAM), the Malaysian Private Dental Practitioners' Association (MPDPA), the Society of Private Medical Practitioners Sarawak (SPMPS), and one Dr Saifulbahri Ahmad. The judicial review is in relation to the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025, which came into effect on May 1. The lawsuit named the Domestic Trade and Cost of Living Minister, Health Minister, and the Federal Government as the first, second, and third respondents, respectively. A three-month grace period from May 1 has been given, during which no compounds would be issued, and the government would instead focus on advocacy and education. According to the court's website, the suit, filed on July 24, is set for case management at the Kuala Lumpur High Court on Aug 22. The statement of claim filed on July 24 seeks a declaration that the ministry's order was void and tainted with illegality, irrationality, unreasonableness, disproportionality, and impropriety. The plaintiffs requested that the enforcement of the ministry's order "insofar as its application to private healthcare facilities and/or registered medical practitioners and dentists" be stayed until the judicial review case is concluded. They argued that the Domestic Trade and Cost of Living Minister breached principles of natural justice by making the decision without consulting registered medical practitioners represented by the MMA. The group stated that while the regulation aims to curb profiteering, it has led to unwarranted competition among drug providers, focusing solely on drug prices. Dr Dzulkefly said the ministry will allow the law to take its course with regard to the legal suit naming him. "I have no problems with it. Let the judicial process take its course. We have to respect this process," he added. Regarding enforcement of the ruling, Dr Dzulkefly said the ministry will continue with educational enforcement and advocacy for the time being. However, he did not specify the duration of the advocacy period before those flouting the rule would be penalised.
